Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy

The ongoing pandemic of coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), needs better treatment options both at antiviral and anti-inflammatory levels. It has been demonstrated that the aminothiol cysteamine, an already human applied drug,...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonzi, Tonino, Aiello, Alessandra, Petrone, Linda, Najafi Fard, Saeid, D’Eletto, Manuela, Falasca, Laura, Nardacci, Roberta, Rossin, Federica, Delogu, Giovanni, Castilletti, Concetta, Capobianchi, Maria Rosaria, Ippolito, Giuseppe, Piacentini, Mauro, Goletti, Delia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750154/
https://www.ncbi.nlm.nih.gov/pubmed/35011614
http://dx.doi.org/10.3390/cells11010052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750154/
https://www.ncbi.nlm.nih.gov/pubmed/35011614
http://dx.doi.org/10.3390/cells11010052

Ejemplares similares